Maravai LifeSciences Holdings, Inc.

NasdaqGS:MRVI 주식 보고서

시가총액: US$1.8b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Maravai LifeSciences Holdings 미래 성장

Future 기준 확인 1/6

Maravai LifeSciences Holdings (는) 각각 연간 117.7% 및 10.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 104.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 0.09% 로 예상됩니다.

주요 정보

117.7%

수익 성장률

104.1%

EPS 성장률

Life Sciences 수익 성장16.2%
매출 성장률10.3%
향후 자기자본 수익률0.09%
애널리스트 커버리지

Good

마지막 업데이트22 Jun 2024

최근 미래 성장 업데이트

Recent updates

RGA Investment Advisors - Maravai: Two Elite Assets With Other-Worldly Margins Wrapped In One

Jun 12

Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%

May 14
Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%

An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued

Apr 07
An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable

Feb 28
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable

Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price

Dec 19
Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price

Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates

Aug 14
Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates

Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?

Feb 28
Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?

Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value

Nov 01
Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value

Maravai Lifesciences temporarily reinstates Carl Hull as CEO

Oct 19

Maravai LifeSciences appoints former Danaher executive as CEO

Oct 03

Maravai LifeSciences Holdings GAAP EPS of $0.53 beats by $0.15, revenue of $242.73M beats by $9.51M

Aug 04

Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Jun 27
Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 25% Below Its Share Price

Mar 29
Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 25% Below Its Share Price

Maravai Faces Skeptical Investors As Pandemic Enters New Period

Jan 27

Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price Could Signal Some Risk

Dec 02
Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price Could Signal Some Risk

Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 26% Below Its Share Price

Oct 07
Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 26% Below Its Share Price

수익 및 매출 성장 예측

NasdaqGS:MRVI - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/2026350-17N/A278
12/31/2025303-7646913
12/31/2024276-28234213
3/31/2024274-131-3133N/A
12/31/2023289-11961126N/A
9/30/202342025163218N/A
6/30/202354475268314N/A
3/31/2023718153437459N/A
12/31/2022883220519536N/A
9/30/2022907238479495N/A
6/30/2022920248479491N/A
3/31/2022895226478493N/A
12/31/2021799182354369N/A
9/30/2021669150371389N/A
6/30/2021552127308335N/A
3/31/202138178155181N/A
12/31/202028477127152N/A
12/31/2019143-8724N/A
12/31/2018124-18-40N/A

애널리스트 미래 성장 예측

수입 대 저축률: MRVI 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: MRVI 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: MRVI 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: MRVI 의 수익(연간 10.3% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: MRVI 의 수익(연간 10.3% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: MRVI 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 0.1 %).


성장 기업 발견